메뉴 건너뛰기




Volumn 59, Issue 1, 2005, Pages 11-17

Selective COX-2 inhibition with different doses of rofecoxib does not impair endothelial function in patients with coronary artery disease

Author keywords

Coronary artery disease; Cyclooxygenase 2 inhibition; Endothelial function; High sensitivity C reactive protein

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; GLYCERYL TRINITRATE; PLACEBO; ROFECOXIB;

EID: 16244362718     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (5)

References (27)
  • 1
    • 0036229958 scopus 로고    scopus 로고
    • Specific cyclooxygenase-2 inhibitors: What have we learned since they came into widespread clinical use
    • Crofford LJ: Specific cyclooxygenase-2 inhibitors: what have we learned since they came into widespread clinical use. Curr Opin Rheumatol (2002) 14: 225-230.
    • (2002) Curr Opin Rheumatol , vol.14 , pp. 225-230
    • Crofford, L.J.1
  • 2
    • 0035833502 scopus 로고    scopus 로고
    • The coxibs, selective inhibitors of cyclooxygenase-2
    • Fitzgerald GA and Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Eng J Med (2001) 345: 433-442.
    • (2001) N Eng J Med , vol.345 , pp. 433-442
    • Fitzgerald, G.A.1    Patrono, C.2
  • 5
    • 0035910976 scopus 로고    scopus 로고
    • Cyclooxygenase inhibition and thrombogenicity
    • Catella-Lawson F and Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med (2001) 110: 28S-32S.
    • (2001) Am J Med , vol.110
    • Catella-Lawson, F.1    Crofford, L.J.2
  • 8
    • 0037027050 scopus 로고    scopus 로고
    • COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
    • Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG and Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360: 1071-1073.
    • (2002) Lancet , vol.360 , pp. 1071-1073
    • Ray, W.A.1    Stein, C.M.2    Daugherty, J.R.3    Hall, K.4    Arbogast, P.G.5    Griffin, M.R.6
  • 11
    • 0035913126 scopus 로고    scopus 로고
    • Measurement of endothelial function by brachial artery flow-mediated vasodilation
    • Vogel R: Measurement of endothelial function by brachial artery flow-mediated vasodilation. Am J Cardiol (2001) 88: 31E-34E.
    • (2001) Am J Cardiol , vol.88
    • Vogel, R.1
  • 13
    • 0035846658 scopus 로고    scopus 로고
    • Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation
    • Verma S, Raj SR, Shewchuk L, Mather KJ and Anderson TJ: Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation. Circulation (2001) 104: 2879-2882.
    • (2001) Circulation , vol.104 , pp. 2879-2882
    • Verma, S.1    Raj, S.R.2    Shewchuk, L.3    Mather, K.J.4    Anderson, T.J.5
  • 14
    • 0242460486 scopus 로고    scopus 로고
    • Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease
    • Title LM, Giddens K, McInerney MM, McQueen MJ and Nassar BA: Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol (2003) 42: 1747-1753.
    • (2003) J Am Coll Cardiol , vol.42 , pp. 1747-1753
    • Title, L.M.1    Giddens, K.2    McInerney, M.M.3    McQueen, M.J.4    Nassar, B.A.5
  • 16
    • 0037028635 scopus 로고    scopus 로고
    • Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events
    • Bing RJ and Lomnicka M: Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events. J Am Coll Cardiol (2002) 39: 521-522.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 521-522
    • Bing, R.J.1    Lomnicka, M.2
  • 18
    • 0032869042 scopus 로고    scopus 로고
    • Assessment and treatment of endothelial dysfunction in humans
    • Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol (1999) 34: 631-638.
    • (1999) J Am Coll Cardiol , vol.34 , pp. 631-638
    • Anderson, T.J.1
  • 19
    • 0034617245 scopus 로고    scopus 로고
    • The effect of aspirin and two nitric oxide donors on the infarcted heart in situ
    • Yamamoto T, Kakar NR, Vina ER, Johnson PE and Bing RJ: The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. Life Sci (2000) 67: 839-846.
    • (2000) Life Sci , vol.67 , pp. 839-846
    • Yamamoto, T.1    Kakar, N.R.2    Vina, E.R.3    Johnson, P.E.4    Bing, R.J.5
  • 20
    • 0034900837 scopus 로고    scopus 로고
    • Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits
    • Wong E, Huang J, Tagari P and Riendeau D: Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. Atherosclerosis (2001) 157: 393-402.
    • (2001) Atherosclerosis , vol.157 , pp. 393-402
    • Wong, E.1    Huang, J.2    Tagari, P.3    Riendeau, D.4
  • 21
    • 0033015661 scopus 로고    scopus 로고
    • Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages
    • Baker CS, Hall RJ, Evans TJ, Pomerance A, Maclouf J, Creminon C, Yacoub MH and Polak JM: Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol (1999) 19: 646-655.
    • (1999) Arterioscler Thromb Vasc Biol , vol.19 , pp. 646-655
    • Baker, C.S.1    Hall, R.J.2    Evans, T.J.3    Pomerance, A.4    Maclouf, J.5    Creminon, C.6    Yacoub, M.H.7    Polak, J.M.8
  • 22
    • 0032833967 scopus 로고    scopus 로고
    • Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
    • Schonbeck U, Sukhova GK, Graber P, Coulter S and Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol (1999) 155: 1281-1291.
    • (1999) Am J Pathol , vol.155 , pp. 1281-1291
    • Schonbeck, U.1    Sukhova, G.K.2    Graber, P.3    Coulter, S.4    Libby, P.5
  • 23
    • 0037047092 scopus 로고    scopus 로고
    • Cyclooxygenase-2 inhibition and cardiovascular events
    • Pitt B, Pepine C and Willerson JT: Cyclooxygenase-2 inhibition and cardiovascular events. Circulation (2002) 106: 167-169.
    • (2002) Circulation , vol.106 , pp. 167-169
    • Pitt, B.1    Pepine, C.2    Willerson, J.T.3
  • 25
    • 0037022910 scopus 로고    scopus 로고
    • Inflammation and atherosclerosis
    • Libby P, Ridker PM and Maseri A: Inflammation and atherosclerosis. Circulation (2002) 105: 1135-1143.
    • (2002) Circulation , vol.105 , pp. 1135-1143
    • Libby, P.1    Ridker, P.M.2    Maseri, A.3
  • 26
    • 0033966627 scopus 로고    scopus 로고
    • Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANNF Study)
    • Anderson TJ, Elstein E, Haber H and Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANNF Study). J Am Coll Cardiol (2000) 35: 60-66.
    • (2000) J Am Coll Cardiol , vol.35 , pp. 60-66
    • Anderson, T.J.1    Elstein, E.2    Haber, H.3    Charbonneau, F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.